Thomas Bannister

Dr. Thomas Bannister


Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NKNicole M. Kennedy
Nicole M. Kennedy
CSCullen L. Schmid
Cullen L. Schmid
NRNicolette C. Ross
Nicolette C. Ross
KLKimberly M. Lovell
Kimberly M. Lovell
ZYZhizhou Yue
Zhizhou Yue
TBThomas Bannister
Thomas Bannister

15 April 2019 in ACS Catalysis
Verified
Journal Article
Closed access
HLHua Lin
Hua Lin
XPXiaohong Pan
Xiaohong Pan
ABAdam L. Barsamian
Adam L. Barsamian
TKTheodore M. Kamenecka
Theodore M. Kamenecka
TBThomas Bannister
Thomas Bannister

6 June 2018 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
HLHua Lin
Hua Lin
CWChao Wang
Chao Wang
TBThomas Bannister
Thomas Bannister
TKTheodore M. Kamenecka
Theodore M. Kamenecka

28 July 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
HWHui Wang
Hui Wang
CYChunying Yang
Chunying Yang
JDJoanne R. Doherty
Joanne R. Doherty
WRWilliam R. Roush
William R. Roush
JCJohn L. Cleveland
John L. Cleveland
TBThomas Bannister
Thomas Bannister
Novel substituted pteridine-derived inhibitors of monocarboxylate transporter 1 (MCT1), an emerging target for cancer therapy, are reported. The activity of these compounds as inhibitors of lactate transport was confirmed using a 14C-lactate transport assay, and their potency against MCT1-expressing human tumor cells was established using MTT assays. The four most potent compounds showed substantial anticancer activity (EC50 37–150 nM) vs MCT1-expressing human Raji lymphoma cells.

13 November 2014 in Organic Letters
Verified
Journal Article
Open access
XPXiaohong Pan
Xiaohong Pan
TBThomas Bannister
Thomas Bannister
A general synthetic approach to β-carboline-containing alkaloids was developed. Two consecutive palladium-mediated processes, a Sonagashira coupling and a Larock indole annulation reaction, are central to the method. The scope of the approach was investigated and found to be amenable for constructing a variety of biologically significant natural products and also for preparing substituted analogues for optimization and analysis of their biological properties.

24 November 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
ESEdward L. Stahl
Edward L. Stahl
CSCullen L. Schmid
Cullen L. Schmid
AAAgnes Acevedo-Canabal
Agnes Acevedo-Canabal
CRCai Read
Cai Read
TGTravis W. Grim
Travis W. Grim
LBLaura M. Bohn
Laura M. Bohn
Significance: Analgesic tolerance can result upon chronic use of opioid drugs necessitating dose escalation to treat pain. The biased mu opioid receptor agonist SR-17018 maintains antinociceptive efficacy without evidence of tolerance when given chronically to mice. Here, we show that SR-17018 and related compounds are noncompetitive agonists that stabilize the receptor in an active state that can still be blocked by orthosteric antagonists. We propose that this mode of activation may contribute to the biased agonists’ apparent ability to preferentially induce G protein signaling in cellular assays and may underlie the enduring efficacy observed for SR-17018 in vivo.